东方证券股份有限公司 关于重庆西山科技股份有限公司首次公开发行 战略配售限售股上市流通的核查意见 东方证券股份有限公司（以下简称"保荐机构"）作为重庆西山科技股份有 限公司（以下简称"西山科技"或"公司"）首次公开发行股票并在科创板上市 的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等有关规定的要求，对西山科技首次公开发行战略配售限售股上市流通事 项进行了审慎核查，具体情况如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会《关于同意重庆西山科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2023〕804 号）同意注册，公司向社会公开 发行人民币普通股 13,250,367 股，并于 2023 年 6 月 6 日在上海证券交易所科创 板上市。 本次上市流通的限售股为公司首次公开发行战略配售限售股，锁定期自公司 首次公开发行并上市之日起 24 个月。本次上市流通的限售股数量为 441,826 股， 占公司目前股本总数的 0.95%，对应限售股股东数量为 1 名，将于 2025 年 6 ...

本律师同意将本法律意见书随贵公司本次股东大会决议一并公告,并依法对 本法律意见书承担相应的责任。 西山科技 法律意见书 江苏世纪同仁律师事务所 关于重庆西山科技股份有限公司 2024年年度股东大会法律意见书 重庆西山科技股份有限公司: 根据《公司法》《证券法》和中国证监会《上市公司股东会规则》等法律、 法规和规范性文件以及《公司章程》的规定,本所受贵公司董事会的委托,指派 本律师出席公司2024年年度股东大会,并就本次股东大会的召集、召开程序、出 席会议人员资格、召集人资格、表决程序以及表决结果的合法有效性等事项出具 法律意见。 为出具本法律意见书,本律师对本次股东大会所涉及的有关事项进行了审查, 查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本律师根据法律的要求,按照律师行业公认的业务标准、道德规范和勤勉尽 责的精神,现出具法律意见如下: 一、本次股东大会的召集、召开程序 西山科技 法律意见书 经查,贵公司在本次股东大会召开20 目前刊登了会议通知。 2、贵公司本次股东大会于2025年5月21日下午2点30分在公司会议室如期召 开,会议由董事长郭毅军先生主持,会议召开的时间、地点等相关事项与通知 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-021 重庆西山科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 21 日 （二） 股东大会召开的地点：重庆市两江新区康美街道康竹路 2 号西山科技 B 栋行政楼 6 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 44 | | --- | --- | | 普通股股东人数 | 44 | | 2、出席会议的股东所持有的表决权数量 | 24,747,179 | | 普通股股东所持有表决权数量 | 24,747,179 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 54.7624 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 54.762 ...

Core Points - The annual general meeting of Chongqing Xishan Technology Co., Ltd. is scheduled for May 21, 2025, at 14:30, with a combination of on-site and online voting methods [3][5] - The meeting will cover several key proposals, including the 2024 Board of Directors' work report, the 2024 Supervisory Board work report, the 2024 financial settlement report, and the profit distribution plan for 2024 [5][8][9] - The company reported a net profit of 98,666,904.12 yuan for 2024, with a proposed cash dividend of 10.00 yuan per 10 shares, amounting to a total of 45,190,060.00 yuan, which represents 45.80% of the net profit [8][9] - The company’s total assets decreased from 2,318,065,640.21 yuan in 2023 to 1,925,782,570.99 yuan in 2024, primarily due to share buybacks and dividend distributions [25][26] - The company’s operating income for 2024 was 33,638.07 million yuan, down from 36,068.92 million yuan in 2023, while the net profit also decreased from 11,734.41 million yuan in 2023 to 9,866.69 million yuan in 2024 [25][26] Meeting Procedures - Attendees must arrive at least 30 minutes early for registration, and the meeting will be conducted under strict rules to maintain order and protect shareholder rights [2][4] - The agenda includes the election of vote counters, reading of meeting rules, and voting on various proposals [5][7] - The meeting will also include reports from independent directors and a session for shareholder questions and comments [7][13] Financial Performance - The company’s total liabilities increased, with a debt ratio of 8.35% in 2024 compared to 6.79% in 2023 [25][26] - Research and development expenses accounted for 16.42% of operating income in 2024, up from 12.89% in 2023, indicating a focus on innovation [25][26] - The company’s cash flow from operating activities was reported at 39,468.89 million yuan for 2024, down from 68,080.09 million yuan in 2023 [25][26]

重庆西山科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688576 证券简称：西山科技 1 | 2024 年年度股东大会会议须知 . | | --- | | 2024 年年度股东大会会议议程 . | | 议案一 . | | 《关于公司<2024年度董事会工作报告>的议案》 | | 议案二 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 7 | | 《关于公司<2024 年度监事会工作报告>的议案》 . | | 议案三 - | | 《关于公司<2024 年度财务决算报告>的议案》 | | 议案四 | | 《关于 2024 年度利润分配方案的议案》 | | 议案五 ………………………………………………………………………………………………………………………………………………………………………………………… 10 | | 《关于公司 2025 年度董事、高级管理人员薪酬方案的议案》 | | 议案六 | | 《关于公司 20 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-020 重庆西山科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 5 月 16 日（星期五）15:00-16:00 ? 会议召开地点：价值在线（www.ir-online.cn） ? 会议召开方式：网络互动方式 ? 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 5 月 16 日 前 访 问 网 址 https://eseb.cn/1o8423C4Eco 或使用微信扫描下方小程序码进行会前 提问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普 遍关注的问题进行回答。 一、 说明会类型 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日在上 海证券交易所网站（www.sse.com.cn）披露《2024 年年度报告》 《2025 年第一季 度报告》。为便于广大投资者更加全面深入地了 ...

Group 1 - The company reported a revenue of 340 million yuan in 2024, a decrease of 6.7%, and a net profit attributable to shareholders of 100 million yuan, down 15.9% [2] - In Q1 2024, the company achieved a revenue of 66 million yuan, a decline of 11.2%, with a net profit of 11 million yuan, down 55.7% [2] - The gross margin improved to 70.4%, an increase of 0.7 percentage points, mainly due to the increased revenue share from surgical power consumables [2] Group 2 - The surgical power device equipment revenue declined significantly due to external factors affecting bidding, while consumables saw steady growth, increasing by 15.69% year-on-year [3] - The company is a leader in the domestic surgical power device market, continuously expanding into endoscopy and energy surgical equipment, aiming to become a comprehensive solution provider for surgical procedures [4] - The market for surgical power devices in China was valued at 7.2 billion yuan in 2022, with a trend towards single-use consumables gradually replacing reusable ones [4] Group 3 - The company expects a compound annual growth rate of 6.9% in net profit attributable to shareholders over the next three years, driven by the replacement of reusable consumables and the introduction of innovative products [5] - The company has made significant breakthroughs in the field of flexible endoscopy, successfully obtaining registration for new medical devices [4]

一、 说明会类型 证券代码：688576 证券简称：西山科技 公告编号：2025-020 重庆西山科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 五、 联系人及咨询电话 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日在上 海证券交易所网站（www.sse.com.cn）披露《2024 年年度报告》《2025 年第一季 度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 况，公司计划于 2025 年 5 月 16 日（星期五）15:00-16:00 在"价值在线" （www.ir-online.cn）举办重庆西山科技股份有限公司 2024 年度暨 2025 年第一 会议召开时间：2025 年 5 月 16 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 ...

Core Insights - Xishan Technology's stock closed at 62.75 yuan, up 1.29%, with a rolling PE ratio of 34.63 times and a total market value of 2.918 billion yuan [1] - The average PE ratio in the medical device industry is 48.90 times, with a median of 36.41 times, placing Xishan Technology at the 74th position [1] - As of the first quarter of 2025, eight institutions held shares in Xishan Technology, with a total holding of 6.3702 million shares valued at 416 million yuan [1] Company Overview - Chongqing Xishan Technology Co., Ltd. specializes in the research, development, manufacturing, sales, and service of surgical medical devices [1] - Key products include surgical power devices, endoscopic systems, and energy surgical equipment [1] - The company holds three Class III medical device registration certificates and 36 Class II medical device registration certificates, and has led the drafting of six national industry standards related to surgical power devices [1] - Xishan Technology has undertaken several national and local technology projects, including the "Twelfth Five-Year" National Science and Technology Support Program and various innovation and application demonstration projects [1] Financial Performance - For the first quarter of 2025, the company reported operating revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% [2] - The sales gross margin stood at 67.64% [2] - The company's PE (TTM) is 34.63, while the industry average is 48.90 and the industry median is 36.41 [2]

Revenue Performance - In 2024, the company's operating revenue was 336,380,651.11 yuan, a decrease of 6.74% compared to 2023's 360,689,152.26 yuan, indicating challenges in market expansion and potential market share erosion [1] - The surgical power consumables segment grew steadily, with a year-on-year increase of 15.69%, while the surgical power devices and new product equipment saw revenue declines due to external factors such as delayed bidding [1] - Certain products, like breast biopsy needles, experienced a slight revenue drop due to centralized procurement impacts, although neurosurgery, orthopedics, and ENT consumables showed significant growth exceeding 40% [1] Profitability Analysis - The net profit attributable to shareholders was 98,666,904.12 yuan, down 15.92% from 117,344,082.20 yuan in 2023, influenced by increased R&D expenses and reduced government subsidies [2] - R&D expenses rose to 55,239,983.73 yuan, an 18.79% increase, which compressed profit margins, while government subsidies fell from 14,461,373.20 yuan in 2023 to 4,643,974.74 yuan in 2024 [2] - The non-GAAP net profit decreased by 22.45% to 71,710,314.84 yuan, indicating weakened core business profitability and challenges in enhancing main business earnings [2] Earnings Per Share - Basic earnings per share (EPS) for 2024 was 1.97 yuan, down 22.13% from 2.53 yuan in 2023, directly affecting shareholder returns [3] - The non-GAAP EPS fell by 28.14% to 1.43 yuan, further highlighting the decline in profitability and challenges in operational stability [3] Expense Management - Total expenses remained relatively stable, with sales expenses at 87,641,744.80 yuan, a slight increase of 0.06% from 2023, and management expenses rising by 2.87% to 25,253,817.19 yuan [3] - R&D expenses accounted for 16.42% of operating revenue, up from 12.89% in 2023, reflecting a commitment to innovation despite short-term profit impacts [3] R&D Personnel - The number of R&D personnel increased by 19% to 144, indicating a focus on enhancing R&D capabilities [4] - The educational background of R&D staff includes 7 PhDs, 48 Master's degrees, and 84 Bachelor's degrees, suggesting a need for further optimization to attract high-end talent [4] Cash Flow Analysis - Net cash flow from operating activities decreased by 42.03% to 39,468,869.13 yuan, primarily due to increased expenditures on materials, salaries, taxes, and R&D [5] - Cash flow from investing activities improved significantly to 309,379,187.15 yuan, compared to -1,312,509,545.87 yuan in 2023, indicating effective adjustments in investment strategy [5] - Cash flow from financing activities was -502,774,371.32 yuan, reflecting increased outflows due to share buybacks and dividends, emphasizing a focus on shareholder returns [5]